Harrow (HROW) EV to FCF (2010 - 2026)
Harrow (HROW) posted EV to FCF of 147.15 for Q2 2026, down 10.88% on a QoQ basis from 132.71 in Q1 2026, and up 86.65% year-over-year from 78.84 in Q2 2025.
Analysis
Harrow (HROW) EV to FCF (2010 - 2026) Analysis & Trends
Harrow has reported EV to FCF for 17 years, with the latest figure at 147.15 in Q2 2026.
- On a quarterly basis, EV to FCF rose 86.65% year-over-year to 147.15 in Q2 2026; TTM through Jun 2026 was 300.58, a 28.45% decrease from a year earlier, with the FY2025 full-year figure at 40.74, up 184.49% from the prior year.
- EV to FCF was 147.15 for Q2 2026 at Harrow, down from 132.71 in the prior quarter.
- The five-year high for EV to FCF was 651.1 in Q3 2024, with the low at 1102.11 in Q2 2025.
- Average EV to FCF over 5 years is 48.73, with a median of 66.24 recorded in 2024.
- The largest YoY upside for EV to FCF was 446.65% in 2025 against a maximum downside of 408.41% in 2025.
- Over 5 years, EV to FCF stood at 73.89 in 2022, then jumped by 149.47% to 36.55 in 2023, then slumped by 271.24% to 62.59 in 2024, then soared by 446.65% to 216.97 in 2025, then slumped by 167.82% to 147.15 in 2026.
- The last three EV to FCF figures came in at 147.15 (Q2 2026), 132.71 (Q1 2026), and 216.97 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Harrow | 1.42 Bn | 1.33 Bn | 50.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -147.15 |
| Mar 31, 2026 | -132.71 |
| Dec 31, 2025 | 216.97 |
| Sep 30, 2025 | 104.39 |
| Jun 30, 2025 | -1,102.11 |
| Mar 31, 2025 | 45.20 |
| Dec 31, 2024 | -62.59 |
| Sep 30, 2024 | 651.10 |
| Jun 30, 2024 | -216.78 |
| Mar 31, 2024 | -83.00 |
| Dec 31, 2023 | 36.55 |
| Sep 30, 2023 | -249.08 |
| Jun 30, 2023 | 126.61 |
| Mar 31, 2023 | -69.89 |
| Dec 31, 2022 | -73.89 |
| Sep 30, 2022 | -189.29 |
| Jun 30, 2022 | 31.54 |
| Mar 31, 2022 | 236.96 |
| Dec 31, 2021 | -111.50 |
| Sep 30, 2021 | -74.56 |